Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea

NCT01642589 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningitis
Meningococcal Disease

Interventions

BIOLOGICAL: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)
BIOLOGICAL: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed

Sponsor

Sanofi Pasteur, a Sanofi Company